• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Asia

BioWorld Asia

Dec. 21, 2011

View Archived Issues

Scil Technology to Bank $239M+ In Osteoarthritis Deal with Sanofi

LONDON – Scil Technology GmbH has signed up Sanofi SA as commercialization partner for its protein therapy for osteoarthritis in a €180 million (US$235.9 million) plus royalties deal that will see the French pharma company take on all responsibility for further development of the program. Read More

Sygnis Shares Plunge on AX200 Acute Ischemic Stroke Miss

Shares in Sygnis Pharma AG plunged more than 62 percent Friday on news that its lead drug AX200 failed to demonstrate efficacy in a 328-patient Phase IIb trial in acute ischemic stroke. Read More

Erythropoietin Plays a Key Role in Cancer Spread

LONDON – Erythropoietin (EPO), the hormone that stimulates the formation of new red blood cells, is released in response to tumors and helps provide them with a more favorable environment for growth and spread, a new study has found. Read More

Clinuvel Filing for Scenesse in EU on Phase III Data in EPP

Clinuvel Pharmaceuticals Ltd. plans to complete a European regulatory filing for its lead drug Scenesse (afamelanotide) in the coming weeks, following a Phase III trial in patients with erythropoietic protoporphyria (EPP), which met its primary endpoint. Read More

NeuroSearch Spinouts Acesion, Aniona Picking up CNS Assets

LONDON – NeuroSearch A/S is spinning out two start-ups to take forward programs that were parked in September when the company announced it was restructuring and would be focusing all resources on its Phase III Huntington's disease product, Huntexil. Read More

Oxford's Parkinson's Gene Therapy Improves Symptoms

LONDON – Oxford BioMedica plc can now boast three years' safety data and a sustained improvement in symptoms in all 15 patients treated in the Phase I/II trial of its ProSavin gene therapy for Parkinson's disease, but needs to progress to a higher dose "to provide more certainty" that this is not just a placebo effect, and to be competitive against deep brain stimulation treatment. Read More

Other News To Note

• Apeiron Biologics AG, of Vienna, Australia, said GlaxoSmithKline plc, of London, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, formerly APN01), has initiated a Phase IIa study in patients suffering from acute lung injury. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe